Jian Fang

10PUBLICATIONS
55CO-AUTHORS
Predictive and prognostic markersMolecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)Gene and molecular therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|May 12, 2026
Incidence, Risk Factors, and Impact of Immunotherapy on Brain Metastasis in Extensive-Stage Small Cell Lung Cancer Without Baseline Brain Involvement.

|Feb 25, 2026
SAFFRON-301: a randomised phase III study of sitravatinib in combination with tislelizumab in patients with locally advanced or metastatic non-small cell lung cancer.

Qing Zhou, Bo Gao, Jie Hu

|Dec 01, 2025
Phase 1b Multicenter Study of SG001, a Humanized Anti-PD-1 Antibody, in Patients with Advanced Solid Tumors.

Jian Fang, Ou Jiang, Wei Li

|Sep 09, 2025
Phase II Dose-Randomized Study of Sunvozertinib in Platinum-Pretreated Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Exon 20 Insertion Mutations (WU-KONG1B).

James Chih-Hsin Yang, Mengzhao Wang, Ludovic Doucet

|Nov 28, 2024
Camrelizumab plus carboplatin and pemetrexed as first-line therapy for advanced non-squamous non-small-cell lung cancer: 5-year outcomes of the CameL randomized phase 3 study.

Caicun Zhou, Gongyan Chen, Yunchao Huang

|Jul 17, 2024
Central nervous system efficacy of aumolertinib versus gefitinib in patients with untreated, EGFR-mutated, advanced non-small cell lung cancer: data from a randomized phase III trial (AENEAS).

Shun Lu, Xiaorong Dong, Hong Jian

Pageof 2

Frequent Collaborators

2 joint publications

Yongqian Shu

2 joint publications

Caicun Zhou

2 joint publications

Mengzhao Wang

1 joint publications

Xu Ma